Clinical trial
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV…
NCT00034151 · Achieve Life Sciences, Industry · Completed
Key facts
| NCT number | NCT00034151 |
|---|---|
| Title | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer |
| Official title | A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma |
| Lead sponsor | Achieve Life Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | S-8184 Paclitaxel Injectable Emulsion |
| Enrollment | 52 |
| Start date | Mar 1, 2002 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Apr 24, 2002 |
| Last update posted | Jun 4, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: